- $484.77m
- $445.80m
- $77.36m
Brief: Sight Sciences Q3 Revenue USD 20 Million Vs. IBES Estimate USD 21.6 Million
Brief: Sight Sciences Says Evaluating Guidance For FY 2023 Due To Uncertain Impact Of Reimbursement Coverage For Its Surgical Glaucoma Segment
Brief: Sight Sciences Inc Intends To Reduce Its Headcount By 25 Employees, Or About 10%
U.S. RESEARCH ROUNDUP-Arm Holdings, Expensify, New Relic
U.S. STOCKS ON THE MOVE-First Solar, Canadian Solar
U.S. STOCKS ON THE MOVE-Zions Bancorp, Neurocrine Biosciences, Beauty Health
U.S. STOCKS ON THE MOVE-Guardforce AI, 2seventy Bio, GoDaddy
Sight Sciences tumbles on lowering annual revenue forecast
U.S. RESEARCH ROUNDUP-Block, Caretrust REIT, Sight Sciences
Brief: Sight Sciences Q2 Revenue USD 23.5 Million Vs. IBES Estimate USD 22.4 Million
Brief: Sight Sciences Reaffirms FY Revenue View Of $89 Mln To $94 Mln
Brief: Sight Sciences Says WPS Government Health Administrators Filed Proposed Local Coverage Determination On Micro-Invasive Glaucoma Surgery
Brief: Sight Sciences Q1 revenue USD 18.8 million
Brief: Sight Sciences Defeats 4 Patent Invalidity Challenges Filed By Alcon
Brief: Sight Sciences Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: Sight Sciences Reports Q4 And Full Year 2022 Financial Results
Brief: Sight Sciences Q4 revenue USD 20.5 million
Sight Sciences dips as CFO steps down
Brief: Verana Health And Sight Sciences Collaborate On Glaucoma Research Using Curated Real-World Data From The Iris Registry